Camrelizumab
As of the edition of 20 October 2026, Camrelizumab is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 469, 17 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Lungs and airways; Mouth and teeth; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 48 | 4 | 13 | 1 |
| Phase 1 | 25 | 7 | 4 | 3 |
| Phase 2 | 339 | 37 | 98 | 8 |
| Phase 3 | 54 | 7 | 28 | 5 |
| Phase 4 | 3 | 0 | 3 | 0 |
| All trials | 469 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Atridia | Lead sponsor of trials | 2015 to now |
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2016 to now |
| HRYZ Biotech | Lead sponsor of trials | 2018 to now |
| CrystalGenomics | Lead sponsor of trials | 2023 to now |
| CNBG-Virogin Biotech | Lead sponsor of trials | 2023 to now |
| Hutchmed | Lead sponsor of trials | 2024 to now |